X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs FDC LTD. - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA FDC LTD. ABBOTT INDIA/
FDC LTD.
 
P/E (TTM) x 39.6 21.2 186.2% View Chart
P/BV x 10.2 4.8 212.9% View Chart
Dividend Yield % 0.7 1.0 68.5%  

Financials

 ABBOTT INDIA   FDC LTD.
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
FDC LTD.
Mar-14
ABBOTT INDIA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs6,110144 4,257.8%   
Low Rs3,99679 5,058.2%   
Sales per share (Unadj.) Rs1,552.247.6 3,263.4%  
Earnings per share (Unadj.) Rs188.87.6 2,481.3%  
Cash flow per share (Unadj.) Rs196.49.0 2,180.1%  
Dividends per share (Unadj.) Rs55.002.25 2,444.4%  
Dividend yield (eoy) %1.12.0 53.8%  
Book value per share (Unadj.) Rs796.647.5 1,675.8%  
Shares outstanding (eoy) m21.25177.83 11.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.32.3 139.2%   
Avg P/E ratio x26.814.6 183.1%  
P/CF ratio (eoy) x25.712.3 208.3%  
Price / Book Value ratio x6.32.3 271.0%  
Dividend payout %29.129.6 98.5%   
Avg Mkt Cap Rs m107,37619,784 542.8%   
No. of employees `0003.3NA-   
Total wages/salary Rs m3,9371,221 322.6%   
Avg. sales/employee Rs Th9,929.3NM-  
Avg. wages/employee Rs Th1,185.1NM-  
Avg. net profit/employee Rs Th1,207.7NM-  
INCOME DATA
Net Sales Rs m32,9858,459 390.0%  
Other income Rs m1,170394 297.3%   
Total revenues Rs m34,1558,852 385.8%   
Gross profit Rs m5,2452,070 253.4%  
Depreciation Rs m162249 65.0%   
Interest Rs m3831 123.2%   
Profit before tax Rs m6,2152,184 284.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,203606 363.8%   
Profit after tax Rs m4,0121,353 296.5%  
Gross profit margin %15.924.5 65.0%  
Effective tax rate %35.427.7 127.8%   
Net profit margin %12.216.0 76.0%  
BALANCE SHEET DATA
Current assets Rs m22,6554,355 520.2%   
Current liabilities Rs m6,6811,792 372.8%   
Net working cap to sales %48.430.3 159.8%  
Current ratio x3.42.4 139.5%  
Inventory Days Days6544 145.7%  
Debtors Days Days2925 118.2%  
Net fixed assets Rs m8353,025 27.6%   
Share capital Rs m213179 119.0%   
"Free" reserves Rs m16,7158,243 202.8%   
Net worth Rs m16,9288,453 200.3%   
Long term debt Rs m011 0.0%   
Total assets Rs m24,16210,557 228.9%  
Interest coverage x163.771.4 229.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.40.8 170.4%   
Return on assets %16.813.1 127.9%  
Return on equity %23.716.0 148.1%  
Return on capital %36.923.5 157.1%  
Exports to sales %013.3 0.0%   
Imports to sales %03.3 0.0%   
Exports (fob) Rs mNA1,126 0.0%   
Imports (cif) Rs mNA283 0.0%   
Fx inflow Rs m3691,146 32.2%   
Fx outflow Rs m3,807355 1,071.4%   
Net fx Rs m-3,438791 -434.8%   
CASH FLOW
From Operations Rs m1,5271,485 102.8%  
From Investments Rs m-2,148-620 346.8%  
From Financial Activity Rs m-1,024-753 136.1%  
Net Cashflow Rs m-1,646113 -1,458.9%  

Share Holding

Indian Promoters % 0.0 68.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 4.7 168.1%  
FIIs % 0.1 7.5 1.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 19.0 90.0%  
Shareholders   18,270 23,730 77.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

VINATI ORG. Plunges by 5%; BSE 500 Index Down 1.7% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

VINATI ORG. share price has plunged by 5% and its current market price is Rs 1,364. The BSE 500 is down by 1.7%. The top gainers in the BSE 500 Index are TCS (up 3.9%) and CYIENT LTD (up 3.8%). The top losers are VINATI ORG. (down 5.5%) and ABBOTT INDIA (down 5.2%).

WOCKHARDT LTD. Plunges by 5%; BSE HEALTHCARE Index Down 1.9% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

WOCKHARDT LTD. share price has plunged by 5% and its current market price is Rs 588. The BSE HEALTHCARE is down by 1.9%. The top gainers in the BSE HEALTHCARE Index are BLISS GVS PHARMA (up 1.0%) and THYROCARE TECHNOLOGIES (up 1.0%). The top losers are WOCKHARDT LTD. (down 5.0%) and PFIZER (down 6.1%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 24, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS